drugset / Trial / NCT02323139
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase Ib add-on study of the combination of LDE255 to azacitidine in patients without marrow response after at least 6 cycles of azacitidine.
Timeline
- Start
- 2015-02-10
- Primary completion
- 2018-01
- Completion
- 2018-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LDE255 | Unknown | 200 mg | Oral |
| Subject | LDE255 | Unknown | 400 mg | Oral |
| Subject | LDE255 | Unknown | 800 mg | Oral |
| Background | Azacitidine | Other / unclassified | — | — |